Business context and reporting period
Entity mismatch: The request identifies Opus Genetics, Inc., but the supplied Form 10-Q is for Rexahn Pharmaceuticals, Inc. This summary reflects the filing itself. It covers the quarter and nine months ended September 30, 2016; the financial statements are unaudited. Rexahn was a clinical-stage oncology biopharmaceutical company with no commercial revenue.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2016 and 2015 | $0 in 2016 and 2015 |
| Operating expenses | $3.718 million in 2016; $4.659 million in 2015 | $12.494 million in 2016; $13.896 million in 2015 |
| Net loss | $2.867 million in 2016; $4.027 million in 2015 | $8.782 million in 2016; $11.532 million in 2015 |
| Net loss per share, basic and diluted | $0.01 in 2016; $0.02 in 2015 | $0.04 in 2016; $0.06 in 2015 |
| Net cash used in operating activities | Not separately presented | $11.734 million in 2016; $12.944 million in 2015 |
At September 30, 2016, cash and cash equivalents were $8.392 million and marketable securities were $13.419 million, for combined cash and securities of $21.812 million. Current assets were $22.614 million and current liabilities were $5.502 million. Total liabilities were $5.502 million, including $3.162 million of warrant liabilities; the balance sheet shows no conventional borrowings. Stockholders’ equity was $17.240 million. The filing does not present a gross or operating margin measure; with no revenue, margins are not meaningful.
Material changes versus prior comparable periods
- Third-quarter operating expenses fell 20.2% year over year; nine-month expenses fell 10.1%. General and administrative costs declined 8.7% for the quarter and 3.7% for the nine-month period, mainly due to lower personnel costs and professional fees.
- Research and development costs declined 25.9% for the quarter and 13.3% for the nine months, primarily because of lower drug-manufacturing costs; reduced manufacturing expense was partly offset by higher clinical costs related to enrollment.
- Net losses narrowed, aided in part by noncash unrealized gains on warrant liabilities: $0.968 million for the quarter and $3.942 million for the nine months of 2016. These gains are valuation-driven, not operating cash inflows.
- Cash and cash equivalents decreased $1.807 million from December 31, 2015. Nine-month financing provided $10.122 million net, principally from March and September registered direct offerings. Common shares outstanding increased to 237,368,785 from 197,413,785 at year-end 2015.
Outlook, management commentary, risks and unusual items
Management said cash, cash equivalents and marketable securities should fund current activities for at least the next 12 months, while also stating that additional capital will be needed to continue developing candidates. Management warned that financing may not be available on acceptable terms, or at all, and that failure to raise capital could require reduced R&D activity. The company anticipated losses through 2016 and beyond.
Management expected R&D expenses to rise in the fourth quarter versus the third quarter due to increased trial enrollment and new manufacturing campaigns. Pipeline updates included progression of RX-3117 pancreatic cancer development to stage 2 after meeting predefined stage 1 efficacy criteria, initiation of its bladder cancer trial, ongoing Phase IIa Archexin renal-cell-carcinoma testing, and ongoing Phase I Supinoxin testing. Rexahn planned Phase Ib/IIa Supinoxin development in triple-negative breast and relapsed/refractory ovarian cancers. Outcomes and timing remain uncertain.
Key risks include clinical-trial execution and results, regulatory approvals, dependence on third-party research organizations and manufacturers, intellectual-property protection, and the need for further capital. The company reported approximately $6.180 million in estimated remaining costs under R&D vendor agreements, which may be terminated with notice under their terms. Potential license milestone payments had not been triggered as of September 30, 2016. Warrant liabilities are Level 3 fair-value estimates sensitive to assumptions, including the probability of a fundamental transaction. The filing reported no material change in previously disclosed risk factors and no material change in market-risk exposure.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review subsequent liquidity, operating cash burn and financing needs against management’s at-least-12-month runway statement.
- Assess potential dilution from the 39.955 million increase in shares outstanding during the nine months and 54.527 million outstanding warrants at September 30, 2016.
- Track trial enrollment, efficacy and safety data, manufacturing plans, and the expected timing and cost of clinical programs.
- Evaluate the sensitivity of reported net loss to warrant fair-value gains and the assumptions used to measure the warrant liability.